These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2813479)

  • 41. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice.
    Shafaroodi H; Samini M; Moezi L; Homayoun H; Sadeghipour H; Tavakoli S; Hajrasouliha AR; Dehpour AR
    Neuropharmacology; 2004 Sep; 47(3):390-400. PubMed ID: 15275828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
    Ripley TL; Sanchez-Roige S; Bullmore ET; Mugnaini M; Maltby K; Miller SR; Wille DR; Nathan P; Stephens DN
    Psychopharmacology (Berl); 2015 Sep; 232(18):3431-41. PubMed ID: 26141191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute sensitization to opioid antagonists.
    White-Gbadebo D; Holtzman SG
    Pharmacol Biochem Behav; 1994 Mar; 47(3):559-66. PubMed ID: 8208774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
    June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
    Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High voluntary alcohol consumption, in experimental liver cirrhosis is hardly responsive to opioid antagonist treatment.
    Stasiak A; Fogel WA
    J Physiol Pharmacol; 2008 Mar; 59(1):101-14. PubMed ID: 18441391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of opioidergic system in modulating cost/benefit decision-making in alcohol-preferring AA rats and Wistar rats.
    Oinio V; Sundström M; Bäckström P; Uhari-Väänänen J; Kiianmaa K; Raasmaja A; Piepponen P
    Behav Pharmacol; 2021 Apr; 32(2&3):220-228. PubMed ID: 33229893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of central opioid receptor subtypes in morphine-induced alterations in peripheral lymphocyte activity.
    Mellon RD; Bayer BM
    Brain Res; 1998 Apr; 789(1):56-67. PubMed ID: 9602057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioidergic modulation of ethanol self-administration in the ventral pallidum.
    Kemppainen H; Raivio N; Suo-Yrjo V; Kiianmaa K
    Alcohol Clin Exp Res; 2012 Feb; 36(2):286-93. PubMed ID: 21895714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Morphine preexposure attenuates the aversive properties of opiates without preexposure to the aversive properties.
    Martin GM; Bechara A; van der Kooy D
    Pharmacol Biochem Behav; 1988 Jul; 30(3):687-92. PubMed ID: 3211978
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naltrexone treatment increases the aversiveness of alcohol for outbred rats.
    Hill KG; Kiefer SW
    Alcohol Clin Exp Res; 1997 Jun; 21(4):637-41. PubMed ID: 9194917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization.
    White DA; Holtzman SG
    J Pharmacol Exp Ther; 2005 Jul; 314(1):374-82. PubMed ID: 15843500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects.
    Kolbow J; Modess C; Wegner D; Oswald S; Maritz MA; Rey H; Weitschies W; Siegmund W
    J Clin Pharmacol; 2016 Feb; 56(2):239-45. PubMed ID: 26313157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers.
    Zacny JP; Wroblewski K; Coalson DW
    Psychopharmacology (Berl); 2015 Jan; 232(1):63-73. PubMed ID: 24871705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes.
    Ho WZ; Guo CJ; Yuan CS; Douglas SD; Moss J
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1158-62. PubMed ID: 14560041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dissociable effects of ultralow-dose naltrexone on tolerance to the antinociceptive and cataleptic effects of morphine.
    Tuerke KJ; Beninger RJ; Paquette JJ; Olmstead MC
    Behav Pharmacol; 2011 Sep; 22(5-6):558-63. PubMed ID: 21555938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide.
    Nozaki-Taguchi N; Yaksh TL
    Anesthesiology; 1999 Jan; 90(1):225-34. PubMed ID: 9915332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in mu-opioid receptor density.
    Cowen MS; Rezvani AH; Jarrott B; Lawrence AJ
    Alcohol Clin Exp Res; 1999 Jun; 23(6):1008-14. PubMed ID: 10397284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methylnaltrexone methobromide: the first peripherally active, centrally inactive opioid receptor-antagonist.
    Guay DR
    Consult Pharm; 2009 Mar; 24(3):210-26. PubMed ID: 19555136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversal of morphine-induced urinary retention after methylnaltrexone.
    Garten L; Bührer C
    Arch Dis Child Fetal Neonatal Ed; 2012 Mar; 97(2):F151-3. PubMed ID: 22034654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delta receptor antagonism, ethanol taste reactivity, and ethanol consumption in outbred male rats.
    Higley AE; Kiefer SW
    Alcohol; 2006 Nov; 40(3):143-50. PubMed ID: 17418693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.